Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-25
2011-01-25
Andres, Janet L (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S357000, C546S300000, C546S337000
Reexamination Certificate
active
07875636
ABSTRACT:
The present invention is directed to pyridyl amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.
REFERENCES:
patent: 2798075 (1957-07-01), Rey-Bellet et al.
patent: 3594382 (1971-07-01), Florin et al.
patent: 3679698 (1972-07-01), Beaman et al.
patent: 5607976 (1997-03-01), Englert et al.
patent: 5693650 (1997-12-01), Muller et al.
patent: 5747505 (1998-05-01), Connell et al.
patent: 5925646 (1999-07-01), Connell et al.
patent: 6521663 (2003-02-01), Pan et al.
patent: 6610701 (2003-08-01), Barrow et al.
patent: 6703392 (2004-03-01), Aissaoui et al.
patent: 6897207 (2005-05-01), Cox et al.
patent: 6900231 (2005-05-01), Pan et al.
patent: 6989402 (2006-01-01), Hangeland et al.
patent: 7192950 (2007-03-01), Aissaoui et al.
patent: 7288571 (2007-10-01), Hangeland et al.
patent: 2002/0183519 (2002-12-01), Nar et al.
patent: 2002/0193398 (2002-12-01), Barrow et al.
patent: 2003/0100554 (2003-05-01), Jones et al.
patent: 2003/0199523 (2003-10-01), Snutch
patent: 2006/0074076 (2006-04-01), Termin et al.
patent: 2007/0043038 (2007-02-01), Starck et al.
patent: 2007/0173504 (2007-07-01), Pacofsky et al.
patent: 2008/0039472 (2008-02-01), Lacrampe et al.
patent: 2008/0167287 (2008-07-01), Zhuo et al.
patent: 2008/0318976 (2008-12-01), Wood et al.
patent: 1 760 072 (2007-03-01), None
patent: 1 762 218 (2007-03-01), None
patent: 782 067 (1957-08-01), None
patent: 1 403 264 (1975-08-01), None
patent: WO0039077 (2000-07-01), None
patent: WO0111966 (2001-02-01), None
patent: WO0168609 (2001-09-01), None
patent: WO02051838 (2002-07-01), None
patent: WO03000688 (2003-01-01), None
patent: WO2006032631 (2006-03-01), None
patent: WO2006115652 (2006-11-01), None
patent: WO2007073505 (2007-06-01), None
patent: WO2008064157 (2008-05-01), None
patent: WO2009054982 (2009-04-01), None
patent: WO2009054983 (2009-04-01), None
patent: WO2009054984 (2009-04-01), None
G. Primofiore et al., “Refinement of the Benzodiazepine Receptor Site Topology by Structure-Activity Relationships of New N-(Heteroarylmethyl) Indol-3-Y 1glyoxylamides”, J. of Medicinal Chemistry, vol. 49, No. 8, pp. 2489-2495, XP002457568, 2006.
P. G. Nantermet et al., “P2 Pyridine N-Oxide Thrombin Inhibitors: A Novle Peptidomimetic Scaffold”, Biorganic & Medicinal Chemistry Letters, vol. 15, No. 11, pp. 2771-2775, XP004906893, 2005.
Hanessian et al., “Phenolic P2/P3 Core Motif as Thrombin Inhibitors-Desing, Synthesis, and X-Ray Co-Crystal Structure”, Biorganic & Medicinal Chemistry Letters, vol. 16, No. 4, pp. 1032-1036, XP005237642, 2006.
Data Beilstein, Beilstein Institute for Organic Chemistry, Frankfurt -Main, DE: BRN 6741916, XP002457570, 1983.
Y. Katsura et al., “Thiazoline or Thiazine Derivatives as Nitric Oxide Formation Inhibitors”, Database Accession No. 1998:239552, XP002457571, 1998.
Howell et al., “Synthesis and Characterization of 3-Thiophene Carboxamides Containing a Pyridine Ring: Structure, Electrochemistry, and Complexation”, vol. 358, No. 13, pp. 3711-3723, XP005065590, 2005.
G. Blay et al., “Catalytic Asymmetric Addition of Dimethyizinc to Alpha-Ketoesters, Using Mandelamides as Ligands”, Database Accession No. 2006:207062, XP002457572, 2006.
G. Blay et al., “Enantioselective Additon of Dimethylzinc to Aldehydes Catalyzed by N-Substituted Mandelamide -Ti (IV) Complexes”, vol. 16, No. 11, pp. 1953-1958, XP00492366, 2005.
W. L. Albrecht et al., “3-Substituted Imidazoa1, 5-Alphaupyridines” J. of Heterocyclic Chemistry, vol. 16, No. 7. pp. 1349-1351, XP001106066, 1979.
K. Winterfield et al., “Synthesis of 3-Substittued 2-Azainolizines”, vol. 75, No. 22, pp. 1101-1102, XP002457569, 1963.
B. Lee et al., “Copper (II) Complexes with Novel Chiral Amidate Ligands”, Database Accession No. 2002:100958, 2002.
E. Widy-Tyszkiewicz et al., “Pharmacological Studies on 2-and 4-Pyridylmethylamides of Acetyltropic Acid (PAT-2 and PAT-4”), Database Accession No. 1975:601828, 1975.
N. Nonoyama et al., “Cobalt (II), Nickel (II), and Copper (II) Complexes of Potentially Terdentate N-(2′-Picolyl)-2- PYridylacetamide”, Database Accession No. 1975:557164, 1975.
V. Uebele et al., “Positive Allosteric Interaction of Structurally Diverse T-Type Calcium Channel Antagonists”, Cell Biochem Biophys, pp. vol. 55, pp. 81-93, 2009.
V. Uebele et al., “T-Type Calcium Channels Regulate Cortical Plasticity In-Vivo NR-D-08-7049”, Neurophysiology, vol. 20, pp. 257-262, 2009.
International Search Report, PCT/US2007/008977,Nov. 15, 2007.
International Preliminary Report on Patentability, PCT/US2007/008977, Oct. 23, 2008.
Database Registry, “Benzeneacetamide, 4-[[3-[(4-fluorophenyl)methly]-1,2,4-thiadiazol-5-y]oxy]-N-(2-pyridinylmethyl)”, Registry No. 855509-20-5:, XP002513628, Jul. 15, 2005.
Database Registry, “4-[[3-[[(3-methoxyphenyl)methyl]-1,2,4-thiadiazol-5-yl]oxy]-N-(2-pyridinylmethyl)-”Registry No. 854170-18-6:, XP002513629, Jul. 8, 2005.
Database Registry, “4-(1,4-dihydro-4-oxo-2-thioxo-3(2H)-quinaz olinyl)-N-(2-pyridinylmethyl)”, Registry No. 689763-76-6, XP002513630, Jun. 6, 2004.
Database Registry, “4-(2-methyl-3H-Imidazo(4,5-b)pyridin-3-yl)-N-(2-pyridinylmethyl)”, Registry No. 931970-35-3, XP002513623, Apr. 23, 2007.
Database Registry, “4-(1,4-Dihydro-2,4-Dioxo-3(2H)-quinazoliny 1)-N-(2-pyridinylmethyl”, Registry No. 896376-19-5, XP00251624, Jul. 27, 2006.
Database Registry, “Benzeneacetamide, 4-[(2-ethyl-3H-imidazo[4,5-b]pyridin-3-yl)-N-(2-pyridinylmethyl)”, Registry No. 894181-12-5, XP002513625, Jul. 18, 2006.
Database Registry, “Benzeneacetamide, 4-(2-oxo-1-pyrrolidinyl)-N-(2-pyridinylmethyl)”, Registry No. 931630-57-8, XP002513626, Apr. 22, 2007.
Barrow James C.
Reger Thomas S.
Yang Zhi-Qiang
Andres Janet L
Devlin Gerard M.
Merck Sharp & Dohme Corp.
Robinson Binta M
Thies J. Eric
LandOfFree
Pyridyl amide T-type calcium channel antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyridyl amide T-type calcium channel antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridyl amide T-type calcium channel antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2685769